Daily Vitamin D Supplementation Compared to a Loading Dose and Monthly Supplementation in Elderly Nursing Home Residents
NCT ID: NCT01168544
Last Updated: 2013-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
160 participants
INTERVENTIONAL
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
primary objective of this study is:
* to investigate whether with a loading dose based on body weight and baseline serum 25(OH)D level more patients reach adequate serum 25(OH)D levels compared to 800 IU a day.
* to determine the best consolidation treatment.
Secondary objective
* is a loading dose based on body weight and baseline serum 25(OH)D level safe to use in residents of nursing homes.
* is there a relation between the increase in serum 25(OH)D level and muscle strength (handgrip strength).
* is there a relation between the increase in serum 25(OH)D level and mobility (2 minute walk test).
Study design:
Randomised trial with 3 study groups:
* Group 1a. loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy.
* Group 1b. loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy.
* Group 2. 800 IU vit D3/ dag.
Study population:
Vitamine D deficient residents of nursing homes, 65 years or older.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correction of Vitamin D Inadequacy in Nursing Home Residents
NCT00204906
Optimizing Vitamin D in the Elderly
NCT01554241
Vitamin D Administration in the Nursing Home
NCT00204919
Oral Vitamin D Supplementation in Elderly Women
NCT00575835
Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels
NCT01170494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
loading dose and 50.000 IU vit D3/month
Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
loading dose Vitamin D and 50.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
Loading dose and 25.000 IU vit D3/month
Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
loading dose and 25.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
800 IU vit D3/dag
800 IU vit D3/dag
Vitamin D 800 IU /day
800 IU vit D3/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
loading dose Vitamin D and 50.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
loading dose and 25.000 IU vit D3/month
loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
Vitamin D 800 IU /day
800 IU vit D3/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 65 years
* Vitamin D deficiency (serum 25- hydroxycholecholecalciferol (25(OH)D3 \< 50 nmol/l)
* Informed Consent
Exclusion Criteria
* Life expectancy \< 1/2 year
* Multivitamin use including \> 400 IE vit D
* Non-functional dominant arm
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rijnstate Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alysis Zorggroep
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
D.T.W. Salemink, Drs.
Role: PRINCIPAL_INVESTIGATOR
Alysis Zorggroep
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alysis Zorggroep, verpleeghuis zevenaar
Zevenaar, Gelderland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LTC 712-050710
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.